Zevra Therapeutics
ZVRA
89 hedge funds and large institutions have $80.7M invested in Zevra Therapeutics in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 36 reducing their positions, and 7 closing their positions.
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
59% more call options, than puts
Call options by funds: $707K | Put options by funds: $446K
6% more funds holding
Funds holding: 84 → 89 (+5)
3.04% more ownership
Funds ownership: 31.25% → 34.29% (+3%)
3% less capital invested
Capital invested by funds: $83M → $80.7M (-$2.36M)
39% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$6.21M |
| 2 |
ACM
Altium Capital Management
New York
|
+$2.1M |
| 3 |
6CM
683 Capital Management
New York
|
+$1.59M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$794K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$558K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.06M |
| 2 |
AC
Armistice Capital
New York
|
-$1.76M |
| 3 |
VF
Virtu Financial
New York
|
-$177K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$161K |
| 5 |
Barclays
London,
United Kingdom
|
-$150K |
ZVRA Hedge Fund Activity: Q1 2024 in Review
89 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q1 2024, worth a combined $80.7M — down 2.8% from $83M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ZVRA positions and 7 closed out — a net gain of 5 holders — while 22 added to existing stakes and 36 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $6.21M. The largest seller was Citadel Advisors, cutting an estimated $2.06M.
- 89 institutional investors held Zevra Therapeutics (ZVRA) as of Q1 2024, up from 84 in Q4 2023.
- Funds reported $80.7M of Zevra Therapeutics stock for Q1 2024, down 2.8% quarter-over-quarter.
- 12 funds opened new Zevra Therapeutics positions in Q1 2024 and 7 closed out, a net change of +5 holders.
- The largest Zevra Therapeutics buyer in Q1 2024 was Woodline Partners, an estimated $6.21M added.
- The largest Zevra Therapeutics seller in Q1 2024 was Citadel Advisors, an estimated $2.06M sold.
Based on aggregated 13F filings for Q1 2024.